The collaboration aims to bring advanced automation to decentralized healthcare settings, supporting improved patient care in oncology.
SPT Labtech announced a collaboration with Illumina to develop an automated sample preparation platform designed to streamline genomics workflows in decentralized healthcare environments.
The partnership will focus on creating a platform that supports laboratories using Illumina’s MiSeq i100 benchtop sequencing system, enabling smaller labs to access the same level of automation and precision as large core facilities. The collaboration aims to help labs support improved patient care in oncology by enabling broader access to high-quality genomic characterization of disease.
“This next phase of collaboration with Illumina reflects our shared focus on enabling efficient and accessible genomics workflows, further expanding SPT Labtech’s presence in the clinical genomics market,” says Rob Walton, chief executive officer at SPT Labtech, in a release. “With the rapid global adoption of Illumina’s MiSeq i100 platform and the recent shipment of its 1,000th system, there is a growing demand from laboratories seeking to perform their sequencing operations in-house, thereby maximizing control and reducing turnaround times.”
Building on Existing Partnership
The collaboration builds on the success of an existing partnership between the companies, including development of automated library preparation methods on SPT Labtech’s firefly platform. The new platform will provide standardized, automated workflows designed to enable laboratories to achieve rapid, high-quality insights closer to where critical decisions are being made.
The solution is designed to make high-quality next-generation sequencing more accessible to labs around the world by bringing advanced automation to laboratories of all sizes and settings, according to the companies. This approach aims to accelerate the delivery of actionable insights from sample to result.
“Labs around the world rely on Illumina for high-quality, reliable insights and end-to-end workflows that make it easier for them to unlock crucial genomic insights faster,” says Todd Christian, senior vice president of services, arrays, and genomic access at Illumina, in a release. “This collaboration builds on that history and doubles down on our commitment to expand access to next-generation sequencing for labs of all sizes, ultimately enabling researchers and clinicians to drive breakthroughs that matter for the patients they serve.”
The novel platform will enable decentralized labs to access automation capabilities that were previously available primarily to large core facilities, potentially reducing turnaround times and increasing control over sequencing operations for smaller laboratory settings.
ID 31222725 © Luchschen | Dreamstime.com
We Recommend for You:
